Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from QuantumPharm, Inc. ( (HK:2228) ).
XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced a significant improvement in its financial performance for the first half of 2025. The company expects a substantial increase in revenue and a turnaround from a net loss to a net profit, primarily driven by its collaboration with DoveTree Medicines LLC using its AI drug discovery platform. This marks the first time the company has achieved half-year profits, indicating a positive shift in its operational and financial trajectory.
The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
Average Trading Volume: 118,665,490
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$28.55B
Find detailed analytics on 2228 stock on TipRanks’ Stock Analysis page.